BACKGROUND AND OBJECTIVE: Artesunate, an anti-malarial drug, elicits an inhibitory effect on pulmonary carcinoma. However, the mechanisms of artesunate activity on pulmonary carcinoma have not been completely elucidated. The aim of this study is to investigate the effect of artesunate on the invasion of human lung adenocarcinoma A549 cells. METHODS: The inhibitory effect of artesunate on the proliferation and invasion of A549 cells was determined in vitro by MTT assay and transwell chamber invasion assay, respectively. A nude mouse model of human lung A549 cell xenograft tumor was established. The inhibitory effect of artesunate on the tumor of the mouse model as well as ICAM-1 and MMP-9 protein expressions were determined by Western blot. RESULTS: A low dose of artesunate ranging between 1.25 μg/L and 5 μg/L did not significantly inhibit the proliferation of A549 cells in vitro. By contrast, 1.25 μg/L artesunate inhibited the invasion of A549 cells in vitro as determined by transwell chamber invasion assay (96.33 ± 6.41 vs 75.43 ± 4.37, P<0.05). Although 10 mg/kg artesunate did not significantly inhibit A549 xenograft tumor proliferation (P>0.05), artesunate decreased the ICAM-1 and MMP-9 protein levels in the mouse model (P<0.05). CONCLUSIONS: Artesunate could inhibit the invasion of human lung adenocarcinoma A549 cells by possibly downregulating ICAM-1 and MMP-9 expressions.
BACKGROUND AND OBJECTIVE:Artesunate, an anti-malarial drug, elicits an inhibitory effect on pulmonary carcinoma. However, the mechanisms of artesunate activity on pulmonary carcinoma have not been completely elucidated. The aim of this study is to investigate the effect of artesunate on the invasion of humanlung adenocarcinoma A549 cells. METHODS: The inhibitory effect of artesunate on the proliferation and invasion of A549 cells was determined in vitro by MTT assay and transwell chamber invasion assay, respectively. A nude mouse model of humanlung A549 cell xenograft tumor was established. The inhibitory effect of artesunate on the tumor of the mouse model as well as ICAM-1 and MMP-9 protein expressions were determined by Western blot. RESULTS: A low dose of artesunate ranging between 1.25 μg/L and 5 μg/L did not significantly inhibit the proliferation of A549 cells in vitro. By contrast, 1.25 μg/L artesunate inhibited the invasion of A549 cells in vitro as determined by transwell chamber invasion assay (96.33 ± 6.41 vs 75.43 ± 4.37, P<0.05). Although 10 mg/kg artesunate did not significantly inhibit A549 xenograft tumor proliferation (P>0.05), artesunate decreased the ICAM-1 and MMP-9 protein levels in the mouse model (P<0.05). CONCLUSIONS:Artesunate could inhibit the invasion of humanlung adenocarcinoma A549 cells by possibly downregulating ICAM-1 and MMP-9 expressions.
Effects of artesunate with different doses on migration and invasion of lung cancer A459 cells. A: 0 μg/L artesunate group; B: 1.25 μg/L artesunate group; C: 2.5 μg/L artesunate group; D: 5 μg/L artesunate group.
不同浓度青蒿琥酯对肺癌A548细胞侵袭、迁移的影响。A:0 μg/L青蒿琥酯组;B:1.25 μg/L青蒿琥酯组;C:2.5 μg/L青蒿琥酯组;D:5 μg/L青蒿琥酯组。Effects of artesunate with different doses on migration and invasion of lung cancer A459 cells. A: 0 μg/L artesunate group; B: 1.25 μg/L artesunate group; C: 2.5 μg/L artesunate group; D: 5 μg/L artesunate group.
The effect of artesunate with different doses on the heavy of A549 cell xenograft tumor (Mean±SD, n=5) (*P < 0.01, when compared with control group)
不同剂量青蒿琥酯对A549细胞移植瘤瘤重影响(Mean±SD, n=5)(*P < 0.01, 与对照组比较)The effect of artesunate with different doses on the heavy of A549 cell xenograft tumor (Mean±SD, n=5) (*P < 0.01, when compared with control group)
The effect of artesunate with different doses on the ICAM-1 and MMP-9 expression in A549 cell xenograft tumor (Mean±SD, n=6) (*P < 0.05, when compared with control group)
不同剂量青蒿琥酯对A549细胞移植瘤ICAM-1和MMP-9蛋白表达影响(Mean±SD, n=6)(*P < 0.05, 与对照组比较)The effect of artesunate with different doses on the ICAM-1 and MMP-9 expression in A549 cell xenograft tumor (Mean±SD, n=6) (*P < 0.05, when compared with control group)
Authors: Jasti S Rao; Christopher Gondi; Chandramu Chetty; Subramanyam Chittivelu; Pushpa A Joseph; Sajani S Lakka Journal: Mol Cancer Ther Date: 2005-09 Impact factor: 6.261
Authors: J Safranek; M Pesta; L Holubec; V Kulda; J Dreslerova; J Vrzalova; O Topolcan; M Pesek; J Finek; V Treska Journal: Anticancer Res Date: 2009-07 Impact factor: 2.480
Authors: Eirini Thanopoulou; George Kotzamanis; Ioannis S Pateras; Nicholaos Ziras; Alexandros Papalambros; Theodoros Mariolis-Sapsakos; Fragiska Sigala; Elizabeth Johnson; Athanassios Kotsinas; Andreas Scorilas; Vassilis G Gorgoulis Journal: Tumour Biol Date: 2012-05-06